Dr. Mullane is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
374 Bartram Rd
M/C 5065
Riverside, IL 60546Phone+1 708-227-5299Fax+1 773-702-8998
Summary
- Dr. Kathleen Mullane is an Infectious Disease specialist in Chicago, IL. She is a Medical Director for PPD, a division of Thermo-Fischer in the department of Pharmacovigilance and is affiliated with University of Chicago Medical Center. She received her medical degree from Midwestern University / Chicago College of Osteopathic Medicine and has been in practice 28 years.
Clinically, she specializes in transplant /immunocompromised infectious disease states and is experienced in general infectious diseases, HIV, COVID-19, C. difficile colitis, healthcare outcomes research. In clinical trials research she has participated in trials involving vaccines, antifungal agents, antiviral agents and antibacterial agents.
Education & Training
- University of Illinois College of Medicine at ChicagoFellowship, Infectious Disease, 1992 - 1994
- University of ChicagoFellowship, Infectious Disease, 1992 - 1994
- Rush University Medical CenterResidency, Internal Medicine, 1989 - 1992
- Chicago College of Osteopathic Medicine at Midwestern UniversityClass of 1989
- University of Illinois College of Medicine at ChicagoPharm D, Clinical Pharmacy, 1982 - 1983
- Philadelphia College of Pharmacy and SciencesPharm D, Clinical Pharmacy, 1980 - 1982
- University of IowaBS Pharmacy, Pharmacy, 1977 - 1980
Certifications & Licensure
- IL State License 1992 - 2026
- American Board of Internal Medicine Infectious Disease
Awards, Honors, & Recognition
- Top Doctor Chicago Magazine, 2012, 2020-2023
- Top Doctor Castle Connelly / US News and World Report, 2012-2023
- Top Doctor US News and World Report, 2012-2023
- Join now to see all
Clinical Trials
- DB289 Versus TMP-SMX for the Treatment of Acute Pneumocystis Jiroveci Pneumonia (PCP) Start of enrollment: 2006 May 01
- A Study of the Safety and Efficacy of CMX001 for the Prevention of CMV Infection in CMV-seropositive HCT Recipients Start of enrollment: 2013 Aug 01
- Study to Assess the Safety and Efficacy of Brincidofovir in Treatment of Early Versus Late Adenovirus Infection Start of enrollment: 2014 Mar 01
- Join now to see all
Publications & Presentations
PubMed
- 2 citationsMSG-15: Super-Bioavailability Itraconazole Versus Conventional Itraconazole in the Treatment of Endemic Mycoses-A Multicenter, Open-Label, Randomized Comparative Trial.Andrej Spec, George R Thompson, Marisa H Miceli, Justin Hayes, Laurie Proia
Open Forum Infectious Diseases. 2024-03-01 - 3 citationsA Phase 3, Randomized, Double-Blind, Comparator-Controlled Study to Evaluate Safety, Tolerability, and Immunogenicity of V114, a 15-Valent Pneumococcal Conjugate Vacci...Marissa Wilck, Oliver A Cornely, Catherine Cordonnier, Juan Diego Velez, Per Ljungman
Clinical Infectious Diseases. 2023-10-13 - 5 citationsImpact of Baseline and Week 2 and Week 4 Posttransplant CMV Cell-Mediated Immunity on Risk of CMV Infections and Mortality in Recipients of Allogeneic Hematopoietic Ce...Ella J Ariza-Heredia, Drew J Winston, Scott D Rowley, Kathleen Mullane, Pranatharthi Chandrasekar
Open Forum Infectious Diseases. 2023-08-01
Journal Articles
- Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients with Moderate COVID-19Robert L Gottlieb, Gerard J Criner, Onyema Ogbuagu, Kathleen M Mullane, Anuj Gaggar, Diana M Brainard, Gregory Huhn, JAMA
- Definitions of Resistant and Refractory Cytomegalovirus Infection and Disease in Transplant Recipients for Use in Clinical TrialsRoy F Chemaly, Kathleen M Mullane, Robin Avery, Raymund R Razonable, Clinical Infectious Diseases
- Misdiagnosis of Bordetella Bronchiseptica Respiratory Infection as Bordetella Pertussis by Multiplex Molecular AssayVera Tesic, Kathleen Mullane, Kathleen G Beavis, Jennifer Pisano, Moira C McNulty, Jennifer L Steinbeck, David Pitrak, Clinical Infectious Diseases
Lectures
- New Insights into the Diagnosis and Treatment of CDI.Park Ridge, IL - 9/17/2013
- New Treatments in the Management of CDI.Lansing, MI - 8/7/2013
- C-Diff Infection: Changing Trends & New Treatments for the Enemy Within.Englewood, CO - 4/27/2013
- Join now to see all
Other
- Prevention, Diagnosis and Management of Opportunistic Infections in Individuals Living with Chronic Graft versus Host Disease.Mullane KM, Living with Chronic GVHD; An Educational Symposium for Patients, Families and Healthcare Professiona
http://bmtinfonet.org/
10/30/2010 - The 2007 Process of Care (TM) Management of Invasive Fungal Infections: Spectrum of Antifungal Therapies.Mullane KM, University of Medicine of New Jersey and Dentistry; Center for Continuing and Outreach Education and
12/1/2007 - Efficacy and Safety of Echinocandin Prophylaxis against Invasive Fungal Infection during Stem Cell Transplantation.Mullane KM, University of Medicine of New Jersey and Dentistry Center for Continuing and Outreach Education and
4/1/2005
Authored Content
- Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients with Moderate COVID-19August 2020
- Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients with Moderate COVID-19August 2020
- Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients with Moderate COVID-19August 2020
- Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients with Moderate COVID-19August 2020
- Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients with Moderate COVID-19August 2020
- Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients with Moderate COVID-19August 2020
- Pubmed bibliograpyJune 2020
- Join now to see all
Press Mentions
- mRNA Vaccines Get Ready for Their Next Act: Fighting CancerSeptember 21st, 2021
- You're More Likely to Have This Symptom with the Delta Variant, Doctors SayAugust 27th, 2021
- New Study Shows One Dose of COVID-19 Is Not Enough to Protect Against Delta VariantJuly 8th, 2021
- Join now to see all
Professional Memberships
- Fellow
- American Society of TransplantationFellow
- American Society of Blood and Marrow TransplantationMember
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: